Dyslipidemias are highly prevalent in chronic kidney disease, end-stage renal disease, and kidney transplant patients. These dyslipidemias are associated with high cardiovascular risk and mortality. Many clinical trials have shown that statin therapy can significantly reduce adverse cardiovascular events in chronic kidney disease patients and kidney transplant recipients. However, three major trials did not show a benefit of statin therapy in end-stage renal disease patients on dialysis. Major guidelines either recommend against the use of statins in patients on dialysis or provide no recommendations about statin use for this complex patient population. As a result, we suspect many patients on dialysis are not on statins, even if they have known atherosclerotic cardiovascular disease. When these patients receive kidney transplants, the risk of adverse cardiovascular events increases in the peri-operative period. Although there are no randomized clinical trials looking at statin use in these patients, we suggest that statin use be considered in patients with a history of atherosclerotic cardiovascular disease, to potentially minimize peri-operative cardiovascular complications.
| INTRODUC TI ON
Atherosclerotic cardiovascular disease (ASCVD) continues to be the leading cause of death in the United States, and chronic kidney disease (CKD) is a known risk factor for ASCVD. 1, 2 Many studies have
shown that the incidence of ASCVD increases with a decrease in glomerular filtration rate (GFR). [3] [4] [5] [6] [7] [8] Thus, end-stage renal disease (ESRD) patients have the highest ASCVD risk among CKD patients. 8, 9 The HEMO (hemodialysis) study clearly demonstrated a high prevalence (about 80%) of ASCVD in patients on hemodialysis. 10 A subanalysis of the HEMO study showed that 39% of the patients had ischemic heart disease, 40% had congestive heart disease, 31% had arrhythmias, and 63% had other heart diseases. 11 The Kidney Early Evaluation Program (KEEP) screened 100 000 people with kidney disease and found that cardiovascular disease risk increases by 15%
for every increasing stage of CKD. 12 Although kidney transplantation significantly improves patient survival compared to dialysis, cardiovascular outcomes remain worse among kidney transplant recipients (KTRs) than in the general population. [13] [14] [15] [16] ASCVD remains the number one cause of mortality and morbidity in this patient population. 17 The spectrum of ASCVD not only involves coronary artery disease (CAD), but also involves chronic heart failure (CHF), sudden cardiac death, and arrhythmias. As per one study of over 53 000 patients, a markedly increased risk of acute coronary syndrome was observed in the first three months after kidney transplant surgery. 18 Concurrent diabetes mellitus, proteinuria, poor nutritional status, and dyslipidemias are common in CKD patients. 19 Dyslipidemias are a well-known risk factor for ASCVD. 20 Many studies have shown that dyslipidemia leads to accelerated atherosclerosis, which increases the risk of ASCVD. 21, 22 Decreased GFR further accelerates the atherosclerosis with calcium and phosphorous metabolism abnormalities. 23 The combination of dyslipidemia and low GFR exponentially increases the risk of ASCVD in this special patient population.
Many studies have shown that cardiovascular events are significantly higher in patients with CKD as compared to the general population. 24, 25 But unfortunately, dyslipidemias in CKD, ESRD, and kidney transplant recipients (KTRs) are often underdiagnosed and undertreated. 26 Lack of management guidelines for dyslipidemias in CKD and ESRD population is part of the problem. Further, there are no studies to guide the lipid management in the CKD and ESRD patients who are on the wait list for kidney transplant. The purpose of this article was to review the current literature on the management of lipids in this high-risk and complicated group of patients and address how this literature might apply to patients who are on the wait list for kidney transplant, to reduce their cardiovascular mortality in the pre and post-transplant period.
| LIPID MANAG EMENT IN PATIENTS WITH CK D
In 2011, Baigent et al conducted a randomized controlled double-blind trial with more than 9000 patients to see the efficacy of lipid-lowering therapy in CKD and ESRD patients with no history of CAD (The Study of Heart and Renal Protection [SHARP] trial; reduction in all-cause mortality in patients on simvastatin compared to patients on placebo [P = 0.0003]. The study did not find significant reduction in major vascular events in the first year, but subsequently it was highly significant during each separate year. In the
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Trial Evaluating Rosuvastatin (JUPITER), CKD patients receiving rosuvastatin had a reduction in myocardial infarction, ischemic stroke, and cardiovascular mortality by 45% compared to placebo group. producing an absolute reduction in major vascular events of about 11 per 1000 over 5 years. It also showed that the relative effects of statins were the same in people with GFR <60. 30 These results were confirmed by many other meta-analyses which showed that lipidlowering therapies can effectively reduce the cardiovascular and all-cause mortality in patients with CKD. [31] [32] [33] [34] Although the SHARP trial failed to show that statin can slow the progression of CKD, several other trials showed that effectively treating dyslipidemias can slow the progression of CKD. [35] [36] [37] None of these studies showed any significant side effects associated with lipid use including hepatitis, cancers, or rhabdomyolysis. Also, none of these studies showed any effect of lipid on the CKD progression.
Based on these studies, Kidney Disease: Improving Global
Outcomes (KDIGO) in 2013 published their guidelines on the management of lipids in CKD patients. These guidelines recommended that patients over 50 years of age with CKD stages I or II should be on statins, while patients with CKD stages III, IV, and V (not on dialysis) should be on statin plus ezetimibe. KDIGO also recommends that CKD patients between 18 and 49 years old with CAD, diabetes, or prior ischemic stroke should be on statins (Table 2) . 38 The TA B L E 3 ACC/AHA guidelines regarding initiation of statins in CKD, dialysis, and transplant patients high-risk patients, the goal non-HDL cholesterol should be less than 130 mg/dL and LDL cholesterol should be <100 mg/dL (Table 4) . 40 However, none of these guidelines recommended the use of statins in patients on dialysis (hemodialysis or peritoneal dialysis).
| US E OF S TATIN S IN PATIENTS ON DIALYS IS
Despite Even the subset of patients with a history of heart disease did not benefit from statin treatment. 42 A meta-analysis conducted by the Cholesterol Treatment Trialists also found no benefit in terms of major vascular events to support statin use in dialysis patients. 30 Based on these findings, KDIGO guidelines advise against the routine use of statins in patients on hemodialysis or peritoneal dialysis for prevention of ASCVD. The guidelines suggested that it is reasonable to continue statins in patients who are already receiving them at the time of dialysis initiation. However, they suggest that the continuation of statins may be associated with less clinical benefit than in patients without kidney failure. 19 However, we note that the rates of ASCVD events in these large statin trials in people with ESRD were lower than expected, those already on statins were excluded, and they mostly were patients over 60 years of age, so their results may be limited by external validity and their findings may represent a type II error. In addition, none focused on the highest risk group for ASCVD events, namely those with pre-existing ASCVD. In addition, Sánchez-Perales et al demonstrated a high incidence of acute myocardial infarction in CKD patients that start dialysis for the first time. This incidence is tripled in patients who start dialysis with a previous diagnosis of CAD. They found that multivessel disease is more common in this patient population. 43 Chung et al conducted a study to evaluate the effect of moderate-to high-intensity statin on mortality and CV outcomes in dialysis patients after acute myocardial infarction. 
| P OS T-TR AN S PL ANT DYS LIPIDEMIA S AND C ARDIOVA SCUL AR MORTALIT Y AND MORB IDIT Y
ASCVD continues to be the major cause of death in KTRs. 45 Multiple risk factors contribute to this increased risk in ASCVD in transplant recipients. In 1992, Gonyea et al 46 found that the prevalence of hyperlipidemia was as high as 80% in KTRs. In the azathioprinecorticosteroid era of immunosuppression, the prevalence of hyperlipidemia was 50%-78%. [47] [48] [49] [50] Hypertriglyceridemia was reported in 80% of the patients on azathioprine-corticosteroid-based immunosuppression. 51 However, with the introduction of calcineurin inhibitors (CNIs), elevations of LDL cholesterol became the most common form of lipid abnormality. 50 Dyslipidemias are even described in the pediatric literature after kidney transplant. 52 Observational data suggest that dyslipidemia is a predictor of cardiovascular events in KTRs. 53 Along with the prevalence of dyslipidemias, the presence of hypertension, obesity, and diabetes is likely to increase the cardiovascular risk in this high-risk population. before and 682 ± 276 AU x min after treatment (P = 0.042). Plasma NO levels also showed a borderline significant increase from 49 ± 30 to 57 ± 37 μmol/L during the treatment period (P = 0.051).
59
Other than their adverse cardiovascular effects, dyslipidemias may also contribute to chronic kidney allograft injury. 60 The above discussion showed that post-transplant dyslipidemia is highly prevalent and treating dyslipidemias in KTRs can significantly improve graft survival.
Since dyslipidemias are found in the majority of the KTRs, co-administration of statins and CNIs is common. Drug-drug interactions between cyclosporine and statins are well known. As cyclosporine is also metabolized by cytochrome P450, it can increase the effect of statins, [61] [62] [63] potentially requiring the use of lower dose statins.
However, multiple studies failed to show an interaction between tacrolimus and the statins. 64, 65 KDIGO and CARI (Caring for Australians with Renal Impairment) guidelines recommend the use of statins in all KTRs. 66 Managing dyslipidemia in KTR should follow the National Kidney Foundation Kidney Disease Outcome Quality Initiative (NKF-KDOQI) guidelines, which state that kidney transplant recipients should be considered at high risk for cardiovascular disease. These guidelines consider that a low-density lipoprotein (LDL) concentration of <100 mg/dL is optimal. 67 The recent NKF-KDOQI guidelines from 2013 do not recommend using LDL cholesterol levels as a guide for identifying individuals with CKD to be treated or as treatment target. They recommend using a risk calculator as guiding therapy for initiation of the statin therapy. However, there are no clear data in KTR for the initiation of statins. 
| PROP OSAL FOR THE US E OF S TATIN S IN PATIENTS WITH KNOWN C ARD I OVA SCUL AR D IS E A S E ON THE WAITING LIS T FOR RENAL TR AN S PL ANTATI ON
Because most studies did not show a clear benefit of using statins in dialysis patients, KDIGO advised against starting statins in dialysis patients. 19 As a result, and based on our own anecdotal experience, we suspect that many patients on dialysis are not on any lipid-low- After adjusting for different risk factors, statin use in these patients was a predictor of lower overall mortality on the wait list (hazard ratio 0.30, 95% confidence interval 0.11-0.79, P = 0.01). The beneficial effect of statins was also supported by a propensity score analysis (P = 0.02). This beneficial effect was more prominent in patients with diabetes, left ventricular hypertrophy (LVH), and smoking. In this study, all patients were censored at renal transplantation. 71 The prevalence of LVH is estimated to be between 16% and 31% in CKD patients with GFR <30 mL/min, increases to 60%-75% prior to starting dialysis, and rises to 90% after initiation of dialysis. 72 Further, one study showed that after 18 months of dialysis, 62% of the patients had increased LV mass volume index and 49% of them overt cardiac failure. 73 The presence of LVH in these patients has been shown to increase CV mortality. 74 Both animal and human studies have suggested that statins reduce the development of LVH and transition of LVH to heart failure. [75] [76] [77] [78] [79] LVH is present in 50% of the KTRs in the first year after transplantation and associated with significant mortality in the KTRs. 80 Based on these studies, we suspect that statin use may significantly reduce postoperative adverse cardiovascular events in KTRs with a significant history of ASCVD. Similarly, patients on dialysis at high ASCVD risk, such as those with genetic dyslipidemias, type II diabetes mellitus, and selected patients with high ASCVD risk scores, also may be considered for statin treatment while awaiting transplant.
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